Over the past month, I’ve been experimenting with two metabolic health platforms in an effort to stay ahead of the latest #personalizednutrition trends. Those two products are Zoe and Stelo, the latter of which I will cover this week and the former next week. Stelo is the first over-the-counter (OTC) continuous glucose monitor (CGM) from Dexcom ($DXCM), a publicly traded biotech company that has historically catered to the type 1 and type 2 diabetic population on insulin. Unlike Abbott’s FreeStyle Libre used by metabolic health platforms like Levels, Dexcom’s prescription and non-prescription sensors monitor blood glucose levels on a 24/7 basis without the need to “tap to scan” data from the device onto the phone. This technology, combined with FDA approval last March, has opened continuous glucose monitoring to anyone diabetic or non-diabetic over 18 who is curious about the impact of their diet and lifestyle on their blood sugar levels. Since its launch last August, Stelo has attracted 140k+ users via its D2C website and newly launched Amazon storefront. Each order comes with two 15-day sensors for a total of $100.